The "unnatural" l-nucleoside beta-l-2'-deoxythymidine (L-dT) is a potent, specific, and selective inhibitor of the replication of hepatitis B virus (HBV), which is currently in Phase III clinical trials. This unit describes, in detail, a semi-large-scale synthesis of l-dT. This convenient methodology produces l-dT in six steps starting with l-ribose and ending with a satisfactory overall yield of l-dT, and may be applied to other 2'-deoxynucleosides, incorporating different heterocyclic bases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/0471142700.nc1403s24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world clinical data-driven modelling on the initiation time of antiviral prophylaxis among pregnant women with chronic hepatitis B infection.
J Hepatol
November 2024
Department of Infectious Disease, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, Shaanxi, 710061, PR China. Electronic address:
Background & Aims: The risk of mother-to-child transmission (MTCT) for pregnant women with chronic hepatitis B (CHB) infection still exists, especially for those with high HBV DNA level. The guidelines for initiating prophylaxis for pregnant women with CHB vary across countries. We aimed to explore the latest prophylaxis initiation time for these women.
View Article and Find Full Text PDFHepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy-A Systematic Review and Meta-Analysis.
Semin Oncol
December 2024
Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Electronic address:
Article Synopsis
- Hepatitis B virus (HBV) reactivation poses a significant risk for cancer patients undergoing chemotherapy, prompting a systematic review of existing studies on this issue from various databases until July 2023.* -
- The review included 86 studies with over 21,000 patients and found an overall HBV reactivation rate of 9%, with higher rates (10%) in patients with blood cancers compared to those with solid tumors (5%).* -
- Key factors like HBV DNA and certain serology markers were linked to higher reactivation rates, while the use of antiviral prophylaxis significantly reduced these rates for patients on specific medications.*
Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors.
World J Gastroenterol
June 2024
Department of Surgery, Mayo Clinic, Jacksonville, FL 32224, United States.
This editorial commented on an article in the titled "Risks of Reactivation of Hepatitis B Virus in Oncological Patients Using Tyrosine Kinase-Inhibitors: Case Report and Literature Analysis" by Colapietro . In this editorial, we focused on providing a more comprehensive exploration of hepatitis B virus reactivation (HBVr) associated with the usage of tyrosine kinase inhibitors (TKIs). It includes insights into the mechanisms underlying HBV reactivation, the temporal relationship between TKIs and HBV reactivation, and preventive measures.
View Article and Find Full Text PDFDFT/TDDFT calculations of geometry optimization, electronic structure and spectral properties of clevudine and telbivudine for treatment of chronic hepatitis B.
Sci Rep
April 2024
Department of Electrical/Electronics and Computer Engineering, Afe Babalola University, Ado-Ekiti, Nigeria.
Chronic hepatitis B remains a worldwide health concern. Presently, many drugs, such as Clevudine and Telbivudine, are recommended for the treatment of chronic hepatitis B disease. For this purpose, the quantum chemical analysis of E (E), ionization potential (IP), electron affinity (EA), electronegativity (EN), chemical hardness (η), chemical potential (μ), chemical softness (S), electrophilicity index (ω), electron accepting capability (ω), electron-donating capability (ω), Nucleophilicity index (N), additional electronic charge (∆N), Optical softness (σ) and Dipole Moment, IR and UV-Vis spectra, molecular electrostatic potential (MEP) profile, Mulliken charge analysis, natural bond orbital (NBO) were examined in this study.
View Article and Find Full Text PDFCreatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4.
Eur J Clin Pharmacol
July 2024
Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Purpose: To study the correlations of genetic variants of telbivudine phosphorylase kinases and telbivudine plasma concentration with creatine kinase elevation in chronic hepatitis B patients who received telbivudine.
Methods: An observational study was performed in China chronic hepatitis B patients receiving telbivudine therapy at 600 mg once daily. Plasma concentration was measured 12 h after taking telbivudine using ultra-performance liquid chromatography-tandem mass spectrometry and SNPs located in RRM2B, TK2, and NME4 was detected by MALDI-TOF mass spectrometry.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!